Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Vivani Medical, Inc./ 10-Q

Quarterly Report · 10-Q

Vivani Medical, Inc.

VANINASDAQEQUITYCurrent

Quarterly Report

Filed May 13, 2024Accepted May 13, 2024, 5:27 PM EDTCIK 1266806Accession 0001753926-24-000959
View company →Permanent SEC source ↗
Share

Company context

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

Current securities

VANINASDAQ · EQUITY · Current
Historical securities (6)
EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · ETF · Historical · closed Oct 22, 2026EYESWNASDAQ · WARRANT · Historical · closed Aug 30, 2022VANIWOTC · WARRANT · Historical · closed Mar 13, 2024VANIWOTC · WARRANT · Historical · closed Mar 13, 2024

Recent company filings

  1. Regulation FD DisclosureOct 30, 2026
  2. Regulation FD DisclosureOct 29, 2026
  3. 424B5 filingSep 25, 2026
  4. Regulation FD DisclosureSep 16, 2026
  5. Regulation FD DisclosureAug 17, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.